Pfizer's Atirmociclib Study Achieves Key Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy PFE?
Source: Newsfilter
Pfizer's stock rose 4.02% as it reached a 20-day high, reflecting positive investor sentiment.
The recent success of Pfizer's FOURLIGHT-1 study, which demonstrated that atirmociclib combined with fulvestrant reduces the risk of disease progression or death by 40%, has been a confirmed catalyst for the stock's movement. This promising result provides new hope for HR+, HER2- breast cancer patients and indicates strong market demand for atirmociclib, further solidifying Pfizer's position in oncology.
The implications of this trial success are significant, as it not only enhances Pfizer's portfolio in cancer treatment but also positions the company favorably for future growth in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Patent Cliffs and Acquisition Challenges
- Patent Cliff Impact: Pfizer is projected to lose up to $18 billion in revenue from 2025 to 2030 due to patent expirations, significantly impacting its financial health as sales from key drugs like Eliquis and Ibrance are expected to decline sharply.
- Acquisition Strategy: In 2023, Pfizer acquired oncology company Seagen for $43 billion and last year purchased Metsera for up to $10 billion, which is developing GLP-1 drugs aimed at enhancing Pfizer's position in the anti-obesity market, although these acquisitions will take time to yield benefits.
- Financial Performance: Despite challenges, Pfizer maintained a strong profit margin of over 12% last year, providing financial support for continued acquisitions and growth opportunities, demonstrating the company's resilience in adversity.
- Investment Risks and Opportunities: Pfizer's stock is currently trading at just nine times its expected future profits, and while the market is bearish on its growth prospects, the company has over 100 drug candidates in its pipeline that could lead to significant growth if approved, making it a stock worth holding for patient investors.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Pfizer's Future Growth Potential Analysis
- Stock Decline: Pfizer's stock has declined nearly 30% over the past five years, and while the dividend yield is high, investor concerns about its growth prospects reflect a cautious market sentiment regarding the company's future performance.
- Patent Cliff Impact: Pfizer faces patent expirations for key drugs like Eliquis and Ibrance, with projected revenue losses of up to $18 billion from 2025 to 2030, compelling the company to accelerate acquisitions and in-house development to offset these losses.
- Acquisition Strategy: In 2023, Pfizer made headlines with its $43 billion acquisition of cancer treatment company Seagen, and last year it acquired Metsera for up to $10 billion, which is developing GLP-1 drugs that could position Pfizer as a significant player in the anti-obesity market.
- Growth Potential: Despite the risk of short-term revenue declines, Pfizer has over 100 drug candidates in its pipeline, and it is expected to secure more approvals in the next three years, thereby providing substantial growth potential for the company.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
GLP-1 Medications Improve Patient Mood, Study Shows
- Mood Improvement Evidence: According to Dr. Angela Fitch, randomized controlled trials indicate that most patients experience mood improvements when treated with GLP-1 medications, suggesting potential psychological benefits of these drugs.
- Monitoring and Observations: At Knownwell, where Dr. Fitch oversees treatment for over 20,000 patients, she noted that they have not observed the emotional flatness described in media reports, indicating the safety and efficacy of GLP-1 treatments.
- Regulatory Developments: The lack of evidence supporting mental health risks has led regulators to remove suicidality warnings from GLP-1 medication labels, reflecting increased confidence in these drugs.
- Comprehensive Care Recommendations: Dr. Fitch advises that patients should receive comprehensive clinical care when obtaining GLP-1 prescriptions, emphasizing that psychological counseling and behavioral management are crucial for addressing mood shifts beyond medication alone.
See More
Pfizer Faces Patent Cliffs and Acquisition Challenges
- Patent Cliff Impact: Pfizer is projected to lose up to $18 billion in revenue from 2025 to 2030 due to patent expirations, significantly impacting its financial health as sales from key drugs like Eliquis and Ibrance are expected to decline sharply.
- Acquisition Strategy: In 2023, Pfizer acquired oncology company Seagen for $43 billion and last year purchased Metsera for up to $10 billion, which is developing GLP-1 drugs aimed at enhancing Pfizer's position in the anti-obesity market, although these acquisitions will take time to yield benefits.
- Financial Performance: Despite challenges, Pfizer maintained a strong profit margin of over 12% last year, providing financial support for continued acquisitions and growth opportunities, demonstrating the company's resilience in adversity.
- Investment Risks and Opportunities: Pfizer's stock is currently trading at just nine times its expected future profits, and while the market is bearish on its growth prospects, the company has over 100 drug candidates in its pipeline that could lead to significant growth if approved, making it a stock worth holding for patient investors.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Pfizer's Future Growth Potential Analysis
- Stock Decline: Pfizer's stock has declined nearly 30% over the past five years, and while the dividend yield is high, investor concerns about its growth prospects reflect a cautious market sentiment regarding the company's future performance.
- Patent Cliff Impact: Pfizer faces patent expirations for key drugs like Eliquis and Ibrance, with projected revenue losses of up to $18 billion from 2025 to 2030, compelling the company to accelerate acquisitions and in-house development to offset these losses.
- Acquisition Strategy: In 2023, Pfizer made headlines with its $43 billion acquisition of cancer treatment company Seagen, and last year it acquired Metsera for up to $10 billion, which is developing GLP-1 drugs that could position Pfizer as a significant player in the anti-obesity market.
- Growth Potential: Despite the risk of short-term revenue declines, Pfizer has over 100 drug candidates in its pipeline, and it is expected to secure more approvals in the next three years, thereby providing substantial growth potential for the company.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
GLP-1 Medications Improve Patient Mood, Study Shows
- Mood Improvement Evidence: According to Dr. Angela Fitch, randomized controlled trials indicate that most patients experience mood improvements when treated with GLP-1 medications, suggesting potential psychological benefits of these drugs.
- Monitoring and Observations: At Knownwell, where Dr. Fitch oversees treatment for over 20,000 patients, she noted that they have not observed the emotional flatness described in media reports, indicating the safety and efficacy of GLP-1 treatments.
- Regulatory Developments: The lack of evidence supporting mental health risks has led regulators to remove suicidality warnings from GLP-1 medication labels, reflecting increased confidence in these drugs.
- Comprehensive Care Recommendations: Dr. Fitch advises that patients should receive comprehensive clinical care when obtaining GLP-1 prescriptions, emphasizing that psychological counseling and behavioral management are crucial for addressing mood shifts beyond medication alone.
See More
